No Stock Yet
Bank of China Securities: dual-target drug use has become the future, it is recommended to pay attention to the company that already has double-resistance technology platform.
According to a research report issued by Bank of China Securities, bispecific antibodies can specifically combine two antigens or different epitopes of one antigen at the same time, and through their mode of action, they can achieve functions that monospecific antibodies cannot achieve, and are expected to solve potential problems such as single-target drug resistance and lack of safety. The overall research and development is too early, the international pharmaceutical giant has entered the bureau, and the domestic market has followed up quickly. It is recommended to pay attention to the companies that already have double-antibody technology platforms, such as Wuxi Biologics, Genscript Biotech Corporation, Kangfang Biological-B, Corning Jerry Pharmaceutical-B, and Platinum Pharmaceutical-B, Sino Biopharmaceutical.
Hong Kong stocks CXO concept stocks rose, Wuxi Apptec rose more than 5%, Zhaoyan new drug rose nearly 5%, Tigermed, Genscript Biotech Corporation rose more than 4%, Wuxi Biologics, Kellein rose nearly 4%.
Genscript Biotech Corporation (1548.HK): the forecast of China Daily meets expectations and is optimistic about the all-round development of CGT.
Hong Kong stocks CXO concept stocks continued to decline
GenScript Biotech Sees Up to $137 Million H1 Net Loss
09:39 PM EDT, 08/07/2022 (MT Newswires) -- GenScript Biotech (HKG:1548) expects to record an adjusted loss of between $115.3 million and $136.6 million for the six months through June 30, compared wit
Hong Kong stocks announce Nuggets | the global leading company in genetic synthesis announces half-yearly results! The net profit of acellular therapy business has increased by 10% to 20%. It has developed into an international biotechnology company cover
[headline announcement Nuggets] Genscript Biotech Corporation (01548): the adjusted net profit of the acellular therapy business is expected to be about US $29 million to US $31.8 million in the first half of the year. Genscript Biotech Corporation issued an announcement that the adjusted net profit of the group business except the cell therapy business (Legend Biotech Corp) maintained steady growth, with an expected growth of about 10.3% to 20.9%. The acellular therapy business (Prosperity) is expected to make an adjusted net profit of approximately $29 million to $31.8 million, compared with approximately $26.3 million for the same period in 2021. The increase mainly comes from group CDMO and synthetic biology.
Futu Morning Post | Federal Reserve mouthpiece: strong non-farm performance in July means it is difficult for the Fed to slow down the pace of interest rate hikes
Federal Reserve Governor Bowman: in the future, you should consider raising interest rates by 75 basis points several times until you see inflation coming down; after oil prices fell below $90, Citi warned: it is expected to continue to fall sharply; the god of stocks has not avoided a sharp fall! Berkshire lost a whopping $53 billion on its portfolio in the second quarter.
Genscript Biotech Corporation: clarification of profit warning
Genscript Biotech Corporation (01548) expects the adjusted net profit of the acellular therapy business to be about $29 million to $31.8 million in the first half of the year.
Zhitong Financial APP News, Genscript Biotech Corporation (01548) issued an announcement that the group's subsidiaries Probio Technology Limited (vigorous Biology) and Legend Biotech Corp Technology Co., Ltd. (Legend Biotech Corp) have completed a series of financing one after another, resulting in fair value losses on non-cash financial liabilities. The company believes that these financing will help vigorous biology improve its research, development and production capacity in gene and cell therapy (GCT) and antibody drug CDMO (contract development and production organization), and help Legend Biotech Corp promote research and development, clinical trial progress and cilta.
No Stock Yet